Robert Bessler Sells 12,371 Shares of LifeStance Health Group (NASDAQ:LFST) Stock

LifeStance Health Group, Inc. (NASDAQ:LFST) Director Robert Bessler sold 12,371 shares of the stock in a transaction that occurred on Monday, December 15th. The shares were sold at an average price of $7.00, for a total value of $86,597.00. Following the completion of the sale, the director directly owned 1,375,989 shares of the company’s stock, valued at approximately $9,631,923. The trade was a 0.89% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Robert Bessler also recently made the following trade(s):

• On Friday, December 12th, Robert Bessler sold 79,630 shares of LifeStance Health Group stock. The stock was sold at an average price of $7.01, for a total transaction of $558,206.30.

LifeStance Health Group Stock Performance

Shares of LFST stock opened at $6.91 on Thursday. The company has a fifty day moving average price of $5.92 and a two-hundred day moving average price of $5.35. LifeStance Health Group, Inc. has a one year low of $3.74 and a one year high of $8.30. The stock has a market cap of $2.69 billion, a P/E ratio of -230.33 and a beta of 1.13. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.58 and a quick ratio of 1.58.

LifeStance Health Group (NASDAQ:LFST) last issued its earnings results on Wednesday, November 5th. The company reported $0.02 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.01) by $0.03. LifeStance Health Group had a negative net margin of 0.67% and a negative return on equity of 0.62%. The business had revenue of $363.81 million during the quarter, compared to the consensus estimate of $355.06 million. During the same period last year, the business posted ($0.02) EPS. LifeStance Health Group’s revenue was up 16.3% on a year-over-year basis. As a group, equities analysts predict that LifeStance Health Group, Inc. will post -0.18 EPS for the current year.

Analyst Ratings Changes

Several research analysts have recently commented on LFST shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of LifeStance Health Group in a research note on Monday. Barclays assumed coverage on shares of LifeStance Health Group in a research report on Tuesday, December 9th. They set an “overweight” rating and a $8.00 price objective for the company. BTIG Research increased their price objective on shares of LifeStance Health Group from $9.00 to $10.00 and gave the company a “buy” rating in a research report on Friday, December 12th. UBS Group lifted their target price on shares of LifeStance Health Group from $9.00 to $10.00 and gave the stock a “buy” rating in a report on Friday, November 7th. Finally, Wall Street Zen cut shares of LifeStance Health Group from a “buy” rating to a “hold” rating in a report on Saturday, October 11th. Two equities research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, LifeStance Health Group has an average rating of “Moderate Buy” and a consensus price target of $8.83.

Institutional Trading of LifeStance Health Group

Institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. boosted its stake in LifeStance Health Group by 19.5% in the third quarter. Vanguard Group Inc. now owns 14,613,535 shares of the company’s stock valued at $80,374,000 after buying an additional 2,383,728 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of LifeStance Health Group by 27.2% in the 3rd quarter. Dimensional Fund Advisors LP now owns 8,363,607 shares of the company’s stock valued at $45,998,000 after purchasing an additional 1,790,694 shares in the last quarter. Wellington Management Group LLP boosted its stake in shares of LifeStance Health Group by 2.3% in the 1st quarter. Wellington Management Group LLP now owns 5,399,293 shares of the company’s stock valued at $35,959,000 after purchasing an additional 123,056 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of LifeStance Health Group by 62.3% during the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,793,336 shares of the company’s stock valued at $26,363,000 after purchasing an additional 1,839,465 shares during the last quarter. Finally, Barclays PLC increased its position in LifeStance Health Group by 74.7% during the 3rd quarter. Barclays PLC now owns 3,508,552 shares of the company’s stock worth $19,297,000 after purchasing an additional 1,499,687 shares in the last quarter. 85.50% of the stock is currently owned by institutional investors.

About LifeStance Health Group

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.